Virological response and resistance profile in highly treatment‐experienced HIV‐1‐infected patients switching to dolutegravir plus boosted darunavir in clinical practice

HIV Medicine ◽  
2021 ◽  
Author(s):  
Daniele Armenia ◽  
Yagai Bouba ◽  
Roberta Gagliardini ◽  
Lavinia Fabeni ◽  
Vanni Borghi ◽  
...  
Keyword(s):  
Clinical Practice ◽  
Virological Response ◽  
Resistance Profile ◽  
Hiv 1

Virological response and resistance profile in HIV-1-infected patients starting darunavir-containing regimens

HIV Medicine ◽  
2016 ◽  
Vol 18 (1) ◽  
pp. 21-32 ◽  
Author(s):  
D Armenia ◽  
D Di Carlo ◽  
G Maffongelli ◽  
V Borghi ◽  
C Alteri ◽  
...  
Keyword(s):  
Virological Response ◽  
Resistance Profile ◽  
Hiv 1

scholarly journals Improved cyclic urea inhibitors of the HIV-1 protease: synthesis, potency, resistance profile, human pharmacokinetics and X-ray crystal structure of DMP 450

1996 ◽  
Vol 3 (4) ◽  
pp. 301-314 ◽  
Author(s):  
C. Nicholas Hodge ◽  
Paul E. Aldrich ◽  
Lee T. Bacheler ◽  
Chong-Hwan Chang ◽  
Charles J. Eyermann ◽  
...  
Keyword(s):  
Crystal Structure ◽  
Human Pharmacokinetics ◽  
Resistance Profile ◽  
X Ray ◽  
Hiv 1

Factors influencing virological response to antiretroviral drugs in cerebrospinal fluid of advanced HIV-1-infected patients

AIDS ◽  
2002 ◽  
Vol 16 (14) ◽  
pp. 1867-1876 ◽  
Author(s):  
Andrea Antinori ◽  
Maria Letizia Giancola ◽  
Susanna Grisetti ◽  
Fabio Soldani ◽  
Lucia Alba ◽  
...  
Keyword(s):  
Cerebrospinal Fluid ◽  
Virological Response ◽  
Antiretroviral Drugs ◽  
Factors Influencing ◽  
Hiv 1

scholarly journals In Vitro Antiviral Activity and Cross-Resistance Profile of PL-100, a Novel Protease Inhibitor of Human Immunodeficiency Virus Type 1

2007 ◽  
Vol 51 (11) ◽  
pp. 4036-4043 ◽  
Author(s):  
Serge Dandache ◽  
Guy Sévigny ◽  
Jocelyn Yelle ◽  
Brent R. Stranix ◽  
Neil Parkin ◽  
...  
Keyword(s):  
Human Immunodeficiency Virus ◽  
Antiviral Activity ◽  
Highly Active Antiretroviral Therapy ◽  
Cross Resistance ◽  
Drug Resistant ◽  
Resistance Profile ◽  
Immunodeficiency Virus ◽  
Hiv 1

ABSTRACT Despite the success of highly active antiretroviral therapy, the current emergence and spread of drug-resistant variants of human immunodeficiency virus (HIV) stress the need for new inhibitors with distinct properties. We designed, produced, and screened a library of compounds based on an original l-lysine scaffold for their potentials as HIV type 1 (HIV-1) protease inhibitors (PI). One candidate compound, PL-100, emerged as a specific and noncytotoxic PI that exhibited potent inhibition of HIV-1 protease and viral replication in vitro (Ki , ∼36 pM, and 50% effective concentration [EC50], ∼16 nM, respectively). To confirm that PL-100 possessed a favorable resistance profile, we performed a cross-resistance study using a panel of 63 viral strains from PI-experienced patients selected for the presence of primary PI mutations known to confer resistance to multiple PIs now in clinical use. The results showed that PL-100 retained excellent antiviral activity against almost all of these PI-resistant viruses and that its performance in this regard was superior to those of atazanavir, amprenavir, indinavir, lopinavir, nelfinavir, and saquinavir. In almost every case, the increase in the EC50 for PL-100 observed with viruses containing multiple mutations in protease was far less than that obtained with the other drugs tested. These data underscore the potential for PL-100 to be used in the treatment of drug-resistant HIV disease and argue for its further development.

scholarly journals Ceftriaxone: rational use by the Pediatric’s department of the Santa Casa’s Hospital of Belo Horizonte, MG

2020 ◽  
Vol 10 (3) ◽  
Author(s):  
Mariana Souza ◽  
Sidnei Silva ◽  
Cláudia Oliveira ◽  
Áquila Portela
Keyword(s):  
Clinical Practice ◽  
Nosocomial Infections ◽  
Microbial Growth ◽  
Bacterial Resistance ◽  
Resistance Profile ◽  
Rational Use ◽  
Medical Indication ◽  
Belo Horizonte ◽  
Low Rate

OBJECTIVE: The present study had as main objective to evaluate the use of ceftriaxone in the Pediatric’s Department of the Santa Casa’s Hospital of Belo Horizonte, MG, as well as the bacterial resistance profile of nosocomial infections in the same period. METHODOS? The study was based on the analysis of 160 antimicrobial forms of patients taking ceftriaxone and containing the main medical indication, as well as other variables: age, time of use and microbial growth in cultures. RESULTS: Regarding the total antibiotics prescribed, only 0.12% corresponded to the use of the cephalosporin, evidencing the low rate of use and the importance of a conscious and directed use of this drug. CONCLUSION: The study shows the rational use of ceftriaxone in the Pediatric’s Department of the Santa Casa’s Hospital of Belo Horizonte, MG, when compared to other antimicrobials, evidencing its importance in pediatric clinical practice, mainly in relation to the reduction of bacterial resistance.

Prevalence of drug resistant mutants and virological response to combination therapy in patients with primary HIV-1 infection

2000 ◽  
Vol 61 (2) ◽  
pp. 181-186 ◽  
Author(s):  
Catherine Tamalet ◽  
Christophe Pasquier ◽  
Nouara Yahi ◽  
Philippe Colson ◽  
Isabelle Poizot-Martin ◽  
...  
Keyword(s):  
Combination Therapy ◽  
Virological Response ◽  
Drug Resistant ◽  
Resistant Mutants ◽  
Hiv 1

Interleukin-7 levels may predict virological response in advanced HIV-1-infected patients receiving lopinavir/ritonavir-based therapy

HIV Medicine ◽  
2003 ◽  
Vol 4 (4) ◽  
pp. 315-320 ◽  
Author(s):  
MR Boulassel ◽  
GHR Smith ◽  
N Gilmore ◽  
M Klein ◽  
T Murphy ◽  
...  
Keyword(s):  
Virological Response ◽  
Interleukin 7 ◽  
Hiv 1
Sign in / Sign up

Export Citation Format

Share Document